Financial Contrast: Bionik Laboratories vs. Artivion

Comparing the medical device companies to determine the better investment

Mar. 27, 2026 at 9:40am

Got story updates? Submit your updates here. ›

Artivion (NYSE:AORT) and Bionik Laboratories (OTCMKTS:BNKL) are both medical device companies, but which one is the better investment? The article compares the two companies based on factors like dividends, risk, profitability, institutional ownership, valuation, and earnings.

Why it matters

This analysis provides investors with a detailed comparison of the two medical device companies to help them determine which stock may be the better investment option based on a range of financial and operational metrics.

The details

The article examines key metrics like net margins, return on equity, return on assets, revenue, earnings per share, and valuation ratios to assess the relative strengths of Artivion and Bionik Laboratories. It also looks at institutional ownership and analyst recommendations to gauge market sentiment around the two companies.

  • The article was published on March 27, 2026.

The players

Artivion, Inc.

A medical device and implantable human tissue manufacturer that provides products for cardiac, vascular, neurologic, and pulmonary procedures.

Bionik Laboratories Corp.

A robotics company that designs, develops, and commercializes physical rehabilitation technologies, prosthetics, and assisted robotic products.

Got photos? Submit your photos here. ›

The takeaway

Based on the analysis, Artivion appears to be the stronger investment option compared to Bionik Laboratories, with higher revenue, earnings, profitability metrics, and a more favorable analyst consensus rating and potential upside.